Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is …
Biotechnology
CA, Burnaby [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
Metric | Q3 | Q1 | Δ in % | |
---|---|---|---|---|
EV/EBITDA | -41.70 | -55.12 | -38.90 | |
Graham Fair Price | -0.11 | 12.61 | 12.62 | |
PEG | -34.83 | 5.46 | -8.37 | |
Price/Book | 4.00 | 3.68 | 3.54 | |
Price/Cash Flow | -100.00 | -75.40 | 0.00 | |
Prices/Earnings | -46.63 | -17.05 | -11.63 | |
Price/Sales | 0.00 | 0.00 | 0.00 | |
Price/FCF | -100.00 | -75.40 | 0.00 | |
Naive Interpretation | member |
01 - Valuation ·
Weak
Fundamentals
Profitability
Metric | Q3 | Q1 | Δ in % | |
---|---|---|---|---|
Gross Profit Margin | 0.00 | 0.00 | 0.00 | |
Operating Margin | 0.00 | 0.00 | 0.00 | |
ROA | 27.78 | -0.05 | -0.07 | |
ROE | -0.08 | -0.05 | 29.07 | |
ROIC | -0.08 | -0.07 | 21.32 | |
Naive Interpretation | member |
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
Metric | Q3 | Q1 | Δ in % | |
---|---|---|---|---|
Debt QOQ | -0.04 | -0.04 | -0.29 | |
Dividends QOQ | 0.00 | 0.00 | 0.00 | |
EBIT QOQ | < 0.005 | -0.10 | -9130.09 | |
EPS QOQ | -0.01 | 0.03 | 125.00 | |
FCF QOQ | 1.00 | -0.29 | -71.29 | |
Revenue QOQ | 0.00 | -1.00 | -100.00 | |
Naive Interpretation | member |
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
Metric | Q3 | Q1 | Δ in % | |
---|---|---|---|---|
Assets Turnover | n.A. | n.A. | n.A. | |
Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
Days Sales Outstanding (DSO) | 0.00 | 0.00 | 0.00 | |
Inventory Turnover | 0.00 | 0.00 | 0.00 | |
Debt/Capitalization | 0.02 | 0.01 | -31.68 | |
Quick Ratio | 21.32 | 31.52 | 47.85 | |
Naive Interpretation | member |
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
Metric | Q3 | Q1 | Δ in % | |
---|---|---|---|---|
Book Value | 9.65 | 11.44 | 18.61 | |
Cash | 7.98 | 9.02 | 12.99 | |
Capex | 0.00 | < 0.005 | -100.00 | |
Free Cash Flow | 0.00 | -0.56 | -100.00 | |
Revenue | 0.00 | 0.00 | 0.00 | |
Naive Interpretation | member |
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad